Archive
1250 articles, sorted by publication time.
HuidaGene’s HG302 trial went for an extended period without publicly disclosing results after a boy in the high-dose group died; a succession of newly revealed child deaths has put the safety monitoring and reporting systems for investigator-initiated trials in the spotlight.
The research team reframed drug development as a learning task: “Which trials should be initiated in the next six months?” The specially trained model clearly outperformed general-purpose AI, but matching historical decisions does not mean it found the optimal strategy.
This pan-TEAD inhibitor targeting the Hippo signaling pathway has entered a first-in-human trial; what the FDA is accelerating is access to communication and review opportunities, while meaningful evidence of efficacy must still await clinical data.
A year-long study tracking more than 1,000 hospitalized patients found that several viruses residing long-term in the human body reactivated during acute infection. Anellovirus signals persisted into recovery and were associated with fatigue and reduced physical function, but the findings do not yet prove that anelloviruses cause long COVID.
The overall results of the phase 3 trial originally showed no clear benefit; after reanalyzing 414 pretreatment biopsy images, the research team found that adding irinotecan may reduce the risks of recurrence and death in patients with high tumor cell density, but this stratification method has not yet undergone independent validation.
Orzeyful directly activates the deficient orexin signaling in patients with narcolepsy type 1, improving both wakefulness and cataplexy in two Phase 3 trials; this mechanistic breakthrough still requires evidence from long-term safety studies and direct comparisons with existing therapies.
Rare loss-of-function variants in FNIP1 are linked to less abdominal and liver fat, lower blood glucose, and higher lean body mass; cell and mouse experiments provide mechanistic clues, but a critical step remains before safe and effective metabolic drugs can be developed.
A chromosome-capture technique designed for small samples linked disease-risk variants back to genes they may regulate and unexpectedly pointed to CLN3; however, the findings remain a preprint, and the functional evidence comes primarily from mouse cells.
The TEMPO pilot program includes a clinician-supervised medication platform for hypertension and an AI health solution integrating continuous glucose and lifestyle data; limited regulatory discretion enables earlier entry into care settings, but does not mean the FDA has confirmed effectiveness.
The research team overlaid AI risk heatmaps from routine H&E slides with spatial proteomics, identifying adjacent regions within the same tumor that differed in molecular activity and risk level. Preliminary performance was promising, but the evidence remains at the preprint and exploratory-validation stage.
This soft-tissue surgical robot integrates four robotic arms into the operating table, initially covering ten upper-abdominal procedures; the real test will be whether hospital adoption, team training, and clinical benefits can withstand everyday use.
The first mRNA influenza vaccine in the United States targets adults aged 50 and older and demonstrated superiority over a standard-dose vaccine in a Phase 3 trial; approval for people aged 65 and older remains contingent on a postmarketing confirmatory study.